systematic review and meta-analysis
DESCRIPTION
The effect of combination treatment with aliskiren and ACEI/ARB on hyperkalaemia and acute kidney injury. Systematic review and meta-analysis. R2 林瀚榮 /Attending Dr. 鄭昌錡. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/1.jpg)
The effect of combination treatment with aliskiren and ACEI/ARB on hyperkalaemia and acute kidney injury
Systematic review and meta-analysis
Ziv Harel et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis BMJ 2012;344:e42
R2 林瀚榮 /Attending Dr. 鄭昌錡
![Page 2: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/2.jpg)
Outline
Introduction
Methods
Results
Outcomes
Discussion
![Page 3: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/3.jpg)
Introduction
RAS
►Block RAS at multiple foci has compelling rationale
► But may be associated with significant toxicity
►First highlighted the danger of dual inhibition with increased risk of acute dialysis and hyperkalaemia
ONTARGET
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
![Page 4: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/4.jpg)
Introduction
Aliskiren
Direct inhibit renin, the most proximal aspect of RAS
.
May be associated with similar adverse effects
Shown to be efficacious either as monotherapy or in
combination with ACEI/ARB Most trials focused on surrogate outcomes and underpowered to provide robust estimates of adverse events
![Page 5: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/5.jpg)
Wood JM, et al. 2003
Aliskiren
• Molecular weight = 609.8• High solubility in water and biological fluids• Non-peptide drug suitable for oral
administration
O
NH
CONH2
OHH2N
CH3O
O
CH3O
![Page 6: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/6.jpg)
Angiotensinogen
Aliskiren Binds to active site of renin
Aliskiren binds to a pocket in the renin molecule, blocking cleavage of angiotensinogen to angiotensin I
Renin
Aliskiren
Adapted from Wood JM, et al. 2003
![Page 7: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/7.jpg)
Renin Angiotensin System Inhibition
Renin Angiotensin SystemPathophysiologic Effects
ACE
Renin
Na+/H2O retentionVasoconstrictionHypertension
AT1 Receptor
Aldosterone
Angiotensinogen
Ang I
Ang II
Gibbons GH. 1998; Adapted from: Müller DN & Luft FC. 2006
· Glomerularvasoconstriction
· Inflammation· Fibrosis
Kidney
· Hypertrophy· Fibrosis· Vasoconstriction
Heart
· Vasoconstriction
Brain
· Hyperplasia hypertrophy· Inflammation· Oxidation· Fibrosis
Vessels
Biological effects
ACEis
Non ACE pathways
ARBs
PRA
Direct renin inhibitor
PRA
(Pro)reninreceptor
Target cell
· Vasoconstriction· Remodelling
Vessels
Kidney
Heart
Direct renin inhibitor
Azizi M et al. 2006;
Feedback Loop
![Page 8: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/8.jpg)
Carried out a systematic review and meta-analyses
To determine whether use in combination is associated with adverse events
Goal of study
Introduction
![Page 9: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/9.jpg)
Introduction
Ovid Medline (1948 to 7 May 2011)
Embase (1980 to 7 May 2011)
Cochrane central register of controlled trials (1993 to 7 May 2011)
Clinical trials registry (www.clinicaltrials.gov)
Novartis clinical trial results database
Abstracts of past five years from conferences of the American Society of Nephrology and the European Renal Association for ongoing or completed trials
Databases
![Page 10: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/10.jpg)
Outline
Introduction
Methods
Results
Outcomes
Discussion
![Page 11: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/11.jpg)
Methods
Study Selection
Aliskiren + ACEI/ARB vs Aliskiren/ACEI/ARB
At Least 4 wks duration
Randomised controlled trials
All available drugs and all dosing regimen
![Page 12: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/12.jpg)
Methods
Validity assessment
Two authors scanned titles and abstracts for initial selection
Selected articles were reviewed in full and independently assessed for eligibility by the same two reviewers
Used the most complete publication Where more than one publication of a trial existed
![Page 13: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/13.jpg)
Diagram
Exclusion Criteria
Combinations with agents other than ACEI/ARB, e.x., telmisartan and hydrochlorothiazide
Enrolled patients receiving chronic dialysis
Abstracts only Risk of bias could not be determined
Observational studies, case series, letters, commentaries, reviews, and editorials
![Page 14: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/14.jpg)
Methods
Outcome Mesures
Primary outcome Hyperkalaemia (>5.5 )
Secondary outcomes Moderate Hyperkalaemia (K: 5.5-5.9)
Acute kidney injury (Cr >2.0)
Severe Hyperkalaemia ( 6.0)≧
![Page 15: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/15.jpg)
Assessment of risk of bias
Methods
Using the predefined checklist of the Cochrane Database of Systematic Reviews
The classification in each category was yes, no, or unclear carried out an overall assessment of the risk of bias based on the responses for the selected criteria
Assessed risk of bias in sequence generation, allocation concealment, blinding, attrition, selection bias, and other biases
![Page 16: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/16.jpg)
Methods
Data extraction and
synthesis
For binary outcome variables
(hyperkalaemia and acute kidney injury)
Two reviewers independently
extracted data by using custom made
data extraction forms
►Risk ratios►Risk differences►Numbers needed to harm (NNH)►95% confidence intervals
![Page 17: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/17.jpg)
Methods
Funnel plot
method
Random effects model
Statistical heterogeneity
• Cochrane Q test (significance set at 0.01)
• I2 values
Accounts to an extent for variability within and between studies To evaluate
publication bias
Data extraction and synthesis
![Page 18: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/18.jpg)
Methods
• Subgroup analyses – For clinical heterogeneity from the characteristics
of study populations and interventions• Age• Sex• Comorbidities
– Chronic kidney disease– Proteinuria– Congestive heart failure– Diabetes
• Aliskiren dosage
![Page 19: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/19.jpg)
Methods
• Retrospective sensitivity analyses– Based on outcome of severe hyperkalaemia, stratified by
patient risk for hyperkalaemia into low and high risk groups– High risk group
• Chronic kidney disease• Diabetes• Decompensated heart failure• Intravascular volume depletion• β blockers• Potassium sparing diuretics• Aldosterone antagonists
– Sensitivity analyses were planned to assess effects after removal of outlier studies identified in funnel plots
![Page 20: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/20.jpg)
Outline
Introduction
Methods
Results
Outcomes
Discussion
![Page 21: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/21.jpg)
Results
• • Inclusion studies
– 841 screened citations met the search criteria– Excluding 38 duplicate citations, 803 citations
were evaluated– 77 were reviewed in detail– 10 eligible randomised controlled studies
were identified and included
![Page 22: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/22.jpg)
Inclusion studies
![Page 23: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/23.jpg)
Results
• Study characteristics– 7/10 studies
• Compare Aliskiren + ARB vs ARB
– valsartan, losartan, or irbesartan
• 5/7 compare Aliskiren + ARB vs Aliskiren
– 2/10 studies• Compare Aliskiren +
unspecified ARB/ACEI vs ARB/ACEI
– 1/10 study• Compare aliskiren + ACEI
vs ACEI/ aliskiren
(7/10) Aliskiren + ARB vs ARB(2/10) Aliskiren + unspecified ARB/ACEI vs ARB/ACEI
(1/10) Aliskiren + ACEI vs ACEI/ aliskiren
![Page 24: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/24.jpg)
Results
• Dosage– Varied among studies– Nearly all reach the maximum recommended
doses for aliskiren and ACEI/ARB• Duration
– 8~36 wks• Study participants
– Mostly male and relatively young– Exclude severe renal impairment
![Page 25: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/25.jpg)
Results
• Concurrent antihypertensive therapy– 6/10 studies
• 4 studies with β blocker• 2 studies with spironolactone
![Page 26: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/26.jpg)
Results
• Risk of bias– The risk of bias was low – 7 studies described the methods used for generation
of the randomisation sequence, whereas six adequately reported details about allocation concealment
– All studies reported blinding of participants and investigators
– Although safety events were monitored and recorded for all included studies, only two studies provided definitions of such outcomes
![Page 27: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/27.jpg)
Results
• Risk of bias– Complete data for hyperkalaemia and acute
kidney injury were available for 10 and 8 studies, respectively
– Withdrawal rates for all studies were less than 20%
– All included studies were sponsored by Novartis
![Page 28: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/28.jpg)
Outline
Introduction
Methods
Results
Outcomes
Discussion
![Page 29: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/29.jpg)
Outcomes - Hyperkalaemia
• Aliskiren + ACEI/ARB vs ACEI/ARB – All 10 studies– n=4814– Significantly higher– Relative risk
• 1.58 (95% CI: 1.24 to 2.02)– Risk difference
• 0.02 (95% CI: 0.01 to 0.04)– Number needed to harm
• 43 (95% CI: 28 to 90)– I2=0%
– Aliskiren + ACEI/ARB vs Aliskiren – 6 studies– n=2974– Significantly higher– Relative risk
• 1.67 (95% CI: 1.01 to 2.79)– Risk difference
• 0.02 (95% CI: 0.03 to 0.01)– Number needed to harm
• 50 (95% CI: 30 to 125)– I2=19%
![Page 30: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/30.jpg)
Outcomes - Hyperkalaemia
Favor combination therapy
Favor monotherapy
Aliskiren + ACEI/ARB vs ACEI/ARB
![Page 31: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/31.jpg)
Outcomes - Hyperkalaemia
Aliskiren + ACEI/ARB vs Aliskiren
![Page 32: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/32.jpg)
Outcomes
Moderated Hyperkalaemia (K: 5.5-5.9)
• Aliskiren + ACEI/ARB vs ACEI/ARB – Significantly increased
risk– Relative risk
• 1.85 (95% CI: 1.18 to 2.91)
– Risk difference • 0.02 (95% CI: , 0.01 to
0.03)– Number needed to harm
• 50 (95% CI: 33 to 100)
• Aliskiren + ACEI/ARB vs Aliskiren – Significantly increased
risk– Relative risk
• 4.04 (95% CI: 2.12 to 7.71)
– Risk difference • 0.03 (95% CI: , , 0.02 to
0.04 )– Number needed to harm
• 33 (95% CI: 25 to 50)
![Page 33: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/33.jpg)
Outcomes
Moderated Hyperkalaemia (K: 5.5-5.9)
Aliskiren + ACEI/ARB vs ACEI/ARB
![Page 34: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/34.jpg)
Outcomes
Severe Hyperkalaemia (K: 6.0)≧
• Aliskiren + ACEI/ARB vs ACEI/ARB – No significantly
increased risk– Relative risk
• 1.12 (95% CI: 0.55 to 2.29)
• Aliskiren + ACEI/ARB vs Aliskiren – No significantly
increased risk– Relative risk
• 0.45 (95% CI: 0.53 to 1.53 )
![Page 35: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/35.jpg)
Outcomes
Severe Hyperkalaemia (K: 6.0)≧
Aliskiren + ACEI/ARB vs ACEI/ARB
![Page 36: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/36.jpg)
Outcomes - Acute kidney injury
• Aliskiren + ACEI/ARB vs Aliskiren – 6 studies– n=3063– No significantly
increased – Relative risk
• 0.80(CI:0.31 to 2.04)– I2=0%
• Aliskiren + ACEI/ARB vs ACEI/ARB – 8 studies– n=4345– No significantly
increased– Relative risk
• 1.14 (95% confidence interval 0.68 to 1.89)
– I2=30%
![Page 37: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/37.jpg)
Outcomes - Acute kidney injury
Aliskiren + ACEI/ARB vs Aliskiren
![Page 38: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/38.jpg)
Outcomes - Acute kidney injury
Aliskiren + ACEI/ARB vs ACEI/ARB
![Page 39: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/39.jpg)
Outcomes
• Subgroup analysis– Not possible from available data
• Retrospective sensitivity analysis– Carried out on the outcome of severe
hyperkalaemia– Stratifying patients with combination therapy
by risk of hyperkalaemia into low and high risk groups
![Page 40: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/40.jpg)
Outcomes - Retropective sensitivity analysis
• High risk groups– 7 studies– n=3141– No significantly higher– Relative risk
• 1.32 (95% CI: 0.64 to 2.74)
– Low risk groups– 3 studies– n=1673– No significantly higher– Relative risk
• 0.42 (95% CI: 0.08 to 2.14)
Severe hyperkalemia with combination therapy
![Page 41: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/41.jpg)
Outcomes - Retropective sensitivity analysis
High risk groups
![Page 42: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/42.jpg)
Outcomes - Retropective sensitivity analysis
Low risk groups
![Page 43: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/43.jpg)
Outcomes
• Publication bias– No evidence of publication bias for the primary
outcome was suggested by visual inspection of the funnel plots
– The effect of two outlying studies on the hyperkalaemia outcome were assessed using a sensitivity analysis
– Removal of each of these studies decreased the magnitude of the effect for the risk of hyperkalaemia
![Page 44: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/44.jpg)
Outline
Introduction
Methods
Results
Outcomes
Discussion
![Page 45: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/45.jpg)
Discussion
• Significance of this study– Hyperkalaemia
• 50% greater in Aliskiren + ACEI/ARB vs ACEI/ARB• 70% greater in Aliskiren + ACEI/ARB vs Aliskiren
– Acute kidney injury• No evidence of a significant difference
![Page 46: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/46.jpg)
Discussion
• Literature review– To date, no published systematic reviews or
meta-analyses have evaluated the safety of combination therapy
– Previously published pooled analyses provided discordant conclusions
![Page 47: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/47.jpg)
Discussion
• Literature review– Weir MR et al 2007 1
• No difference in hyperkalaemia with combined aliskiren + valsartan
• However, only three of the trials we analysed were also analysed by this study
– White WB et al 2010 2
• Hyperkalaemia was higher in aliskiren + ARB compared with ARB alone
1. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264-77.
2. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich) 2010;12:765-75.
![Page 48: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/48.jpg)
Discussion
• Unique of this study– Included studies evaluated by these two
reviews and incorporated six recently completed randomized trials
– The populations studied varied widely, inlcuding HTN, DM, CHF, and recent ACS
– Such a heterogeneous group may increase generalisability, but may also bias the results because these populations possess differential risks for hyperkalaemia and acute kidney injury
![Page 49: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/49.jpg)
Discussion
• Severity of Hyperkalaemia– Significantly increased risk of moderate but not
severe hyperkalaemia– Assessed high and low risk populations of severe
hyperkalaemia in a retrospective sensitivity analysis– The lack of an increased risk of severe hyperkalaemia
persisted in both populations– May also be explained by the close follow-up, which
may mitigate any differences in baseline risk through adjustments in the management of participants with moderate hyperkalaemia
![Page 50: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/50.jpg)
Discussion
• Acute kidney injury– No significantly increased risk– Why?
• May result from close follow-up• Extremely conservative Cr threshold used to define AKI
in the included studies• May missed milder AKI cases• Short duration of follow-up• Hyperkalaemia often ensues shortly • AKI usually occurs later after a superimposed renal
insult
![Page 51: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/51.jpg)
Discussion
• Quality of the evidence– Most of the trials included were of good
quality– Lack of standardisation of Cr assays among
the included studies may affect results
![Page 52: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/52.jpg)
Discussion
• Strengths of this review– First review describing safety associated with
aliskiren– Broad and included published as well as
unpublished sources
![Page 53: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/53.jpg)
Discussion
• Limitations of this review– Pooled the results of studies that were not originally
intended to explore safety outcomes– Many included studies were small, resulting in few
adverse safety events– Confidence intervals were wide– Did not access to original data – Included heterogeneous participants– Most patients had preserved baseline kidney function,
which may limit the likelihood of hyperkalaemia and acute kidney injury
![Page 54: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/54.jpg)
Discussion
• Future research– ALTITUDE Study
• The Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints
– ATMOSPHERE study• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination
on Morbi-mortality in Patients With Chronic Heart Failure• Implications for practice
– Populations are selected with relatively preserved kidney function
– The generalisability of our findings to routine clinical practice is unknown
![Page 55: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/55.jpg)
Conclusion
• The use of aliskiren in combination is associated with a significantly increased risk of hyperkalaemia
• No effect of on the risk of acute kidney injury
![Page 56: Systematic review and meta-analysis](https://reader035.vdocuments.us/reader035/viewer/2022062310/5681673d550346895ddbef62/html5/thumbnails/56.jpg)
Thank You!